Aurobindo Pharma ka Share Bhaaga! Sarkar ki policy se Penicillin-G production mein bada jump

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorKavya Nair|Published at:
Aurobindo Pharma ka Share Bhaaga! Sarkar ki policy se Penicillin-G production mein bada jump
Overview

Bhai log, Aurobindo Pharma ne ekdum mast plan bataya hai! Company apni Penicillin-G ki production ko **10,000 metric tonnes** se zyada karne wali hai agle **12 mahine** mein, aur ismein **sarkari policy** ka bhi full support mil raha hai. Ye ekdum self-reliance ki taraf bada kadam hai!

Policy ka Full Support, Production Speed Up!

So hua yun ki India ki sarkar ne na, Pen-G, 6 APA, aur Amoxicillin jaise zaroori antibiotics par import prices ko ek saal ke liye relax kar diya hai. Company wale isko 'game changer' bol rahe hain, kyunki isse India khud apni antibiotic needs poori kar paega aur supply chain bhi mazboot hogi. Is policy ki madad se, Aurobindo Pharma apna Penicillin-G ka production 10,000 metric tonnes se badha kar 15,000 metric tonnes tak le jaane ka target rakhe hue hai, khaas kar Kakinada SEZ facility mein. Company ka kehna hai ki unke yield levels bhi steady aur improve ho rahe hain.

Global Expansion Bhi Jaari Hai

Sirf India hi nahi, company apni international presence bhi strong kar rahi hai. China mein jo unki OSD facility hai, woh ab 2 billion units ki capacity tak pahunchne wali hai aur is quarter (Q4 FY26) tak EBITDA breakeven karne ki ummeed hai. US mein, Dayton facility commercial operations start kar chuki hai aur FY27 se revenue generate karna shuru kar degi. Raleigh facility bhi regulatory clearance ke baad scale up hogi.

Financial Targets Aur Numbers

Company ko apni EBITDA margins ko 20-21% tak le jaane ka confidence hai FY26 ke liye. Pichhle quarter (Q3 ended Dec 31, 2025) mein revenue ₹8,646 crore raha, jo pichhle saal ke ₹7,979 crore se zyada hai. Current market cap lagbhag ₹67,303 crore hai.

Valuation Aur Analysts Kya Bolte Hain?

Aurobindo Pharma ka P/E ratio 19.17x hai, jo industry average 26.5x aur peer average 45.8x se kaafi kam hai. Indian API sector bhi 5.0% growth predict kar raha hai 2026 mein. Analysts ka bhi consensus 'Buy' rating ka hai, aur unka average 12-month price target ₹1,345.19 ke aas-paas hai, matlab 16% tak ka upside dikh raha hai. Revenue growth bhi 10.0% annual pace se badhne ka andaza hai 2027 tak.

Thoda Risk Bhi Hai Bhai

Par haan, kuch cheezein hain jin par nazar rakhni hogi. US FDA ne unki Unit VII facility mein nine procedural observations record ki hain, jinmein quality control aur data integrity ke issues hain. Aur company ka history bhi pura controversy-free nahi raha hai, jaise 2019 ka lawsuit, 2022 mein ek director ka arrest, aur 2009 mein insider trading ko lekar SEBI ki penalty. Ye sab factors ko dhyan mein rakhna zaroori hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.